학술논문
The Clinical Outcome and Prognostic Factors for Survival by Patients with COVID-19 in a Community Hospital / 市中病院における COVID-19 罹患患者の生命予後と予後因子の検討
Document Type
Journal Article
Author
Akihiro Kindaichi; Atsushi Hisada; Atsushi Morizane; Ayaka Tanaka; Hirofumi Tamaki; Kenji Ina; Satoshi Kayukawa; Takayuki Nambu; Tetsuya Ito; Toshimitsu Koga; Yoshihiro Ota; Yoshiteru Tanaka; Yui Tajima; Yuka Okada; 久田 敦史; 伊奈 研次; 伊藤 哲也; 南部 隆行; 古賀 俊充; 太田 圭洋; 岡田 由加; 森實 篤司; 玉城 裕史; 田中 彩夏; 田中 義輝; 田島 由依; 粥川 哲; 金田一 彰洋
Source
日本病院総合診療医学会雑誌 / JAPANESE JOURNAL OF HOSPITAL GENERAL MEDICINE. 2023, 19(2):74
Subject
Language
Japanese
ISSN
2185-8136
2758-7878
2758-7878
Abstract
Mortality from coronavirus disease 2019 (COVID-19) has decreased since the special approval of therapeutic agents and widespread implementation of vaccination. However, there are only a few reports on the impact of therapeutic agents and vaccination on the clinical outcomes of patients with COVID-19 in community hospitals. Therefore, we conducted a retrospective survey of 90 patients with COVID-19 (including 72 patients receiving dialysis) hospitalized in a single community hospital to analyze their clinical outcomes and prognostic factors. No differences in the frequency of dialysis, diabetes mellitus, malignancy, or smoking history were observed between the survival ( n = 79) and non-survival groups ( n = 11). The percentage of people aged over 75 years, steroid usage, and the levels of C-reactive protein, D-dimer, and interferon-λ3 were significantly higher in the non-survival group than in the survival group, whereas the body mass index was lower in the non-survival group. However, the rate of vaccination and treatment with remdesivir and/or therapeutic antibodies was significantly higher in the survival group. These results suggest that vaccination and treatment with remdesivir and/or neutralizing antibodies contributes to improvement of clinical outcome of patients with COVID-19.